Home > Insider Trading > Filing (0001192482-11-000265)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1301081	Pharmasset Inc	VRUS	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1397329	Michelle M Berrey	303A College Road East Princeton NJ 08540	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-09-01	3,124	$10.83	3,124	No	4	M	Direct
Common Stock	Disposition	2011-09-01	3,124	$65.63	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2011-09-01	3,124	$0.00	3,124	$10.83

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
28,126		2019-10-14	No	4	M	Direct

Footnotes

This transaction is the result of standing instructions set forth in a Rule 10b5 plan previously established by the filer.
The number of shares beneficially owned reflected in Items 5 and 9 of this Form 4 represent a two-for-one stock split (the "Split") of the Issuer's common stock which is structured in the form of a dividend payable on August 31, 2011 to the stockholders of record at the close of business on August 22, 2011.
Represents the weighted average sales price for price increments ranging from $64.99 to $65.99.
The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4.
A total of 25,000 pre-Split (50,000 post-Split) options were granted on 10/14/2009. 25% of the total grant became vested on the first anniversary and 6.25% become vested each quarter thereafter for the following 12 quarters.